Continued treatment of early virologic nonresponders or partial responders with bulevirtide monotherapy for chronic hepatitis delta leads to improvement in virologic and biochemical responses: Results from an integrated analysis at week 96

被引:0
|
作者
Lampertico, Pietro [1 ,2 ]
Wedemeyer, Heiner [5 ]
Brunetto, Maurizia [3 ,4 ]
Bogomolov, Pavel [7 ]
Stepanova, Tatyana [8 ]
Bourliere, Marc [9 ]
Fontaine, Helene [13 ]
Chee, Grace M. [13 ]
Manuilov, Dmitry [13 ]
An, Qi [13 ]
Freismuth, Aurelie [14 ]
Lau, Audrey [13 ]
Da, Ben [13 ]
Flaherty, John F. [13 ]
Mercier, Renee-Claude [13 ]
Frenette, Catherine [13 ]
Osinusi, Anu [13 ]
Gherlan, George Sebastian [15 ,16 ]
Streinu-Cercel, Adrian [17 ]
Zeuzem, Stefan [6 ]
Cornberg, Markus [5 ]
Roulot, Dominique [10 ]
Zoulim, Fabien [11 ]
Aleman, Soo [18 ]
Asselah, Tarik [12 ]
机构
[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Gastroenterol & Hepatol, Milan, Italy
[2] Univ Milan, CRC AM & A Migliavacca Ctr Study Liver Dis, Milan, Italy
[3] Univ Hosp Pisa, Hepatol Unit, Reference Ctr Tuscany Reg Chron Liver Dis & Canc, Pisa, Italy
[4] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy
[5] Hannover Med Sch, Clin Gastroenterol Hepatol Infect Dis & Endocrino, Hannover, Germany
[6] Univ Hosp Frankfurt, Frankfurt, Germany
[7] Moscow Reg Clin Res Inst, State Budgetary Inst Hlth Care Moscow Reg, Moscow, Russia
[8] LLC Clin Modern Med, Moscow, Russia
[9] Hop St Joseph, Marseille, France
[10] Univ Sorbonne Paris Nord, Bobigny, France
[11] Hosp Croix Rousee, Lyon, France
[12] Univ Paris, Hop Beaujon, Clichy, France
[13] Gilead Sci Pty Ltd, Foster City, CA USA
[14] Gilead Sci Pty Ltd, Melbourne, Australia
[15] Carol Davila Univ Med & Pharm, Bucharest, Romania
[16] Dr Victor Babes Fdn, Bucharest, Romania
[17] Matei Bals Natl Inst Infect Dis, Bucharest, Romania
[18] Karolinska Inst, Karolinska Univ Hosp, Stockholm, Sweden
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
278
引用
收藏
页码:102 / 103
页数:2
相关论文
共 34 条
  • [31] Integrated efficacy analysis of 24-week data from two phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose level for treatment of chronic hepatitis delta
    Lampertico, Pietro
    Aleman, Soo
    Blank, Antje
    Bogomolov, Pavel
    Chulanov, Vladimir
    Mamonova, Nina
    Viacheslav, Morozov
    Sagalova, Olga
    Stepanova, Tatyana
    Suri, Vithika
    Manuilov, Dmitry
    Ye, Lei
    Flaherty, John F.
    Osinusi, Anu
    Cornberg, Markus
    Brunetto, Maurizia
    Wedemeyer, Heiner
    JOURNAL OF HEPATOLOGY, 2022, 77 : S828 - S828
  • [32] End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection
    Etzion, Ohad
    Hamid, Saeed Sadiq
    Lurie, Yoav
    Gane, Edward
    Bader, Nimrah
    Yardeni, David
    Nevo-Shor, A.
    Channa, S. M.
    Mawani, Minaz
    Parkash, Om
    Yang, Kyunghee
    Longo, Diane
    Gish, Robert G.
    Glenn, Jeffrey
    Apelian, David
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E32 - E32
  • [33] Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study
    Wedemeyer, Heiner
    Aleman, Soo
    Brunetto, Maurizia
    Blank, Antje
    Andreone, Pietro
    Bogomolov, Pavel
    Chulanov, Vladimir
    Mamonova, Nina
    Geyvandova, Natalia
    Viacheslav, Morozov
    Sagalova, Olga
    Stepanova, Tatyana
    Manuilov, Dmitry
    Suri, Vithika
    An, Qi
    Flaherty, John F.
    Osinusi, Anu
    Zur Wiesch, Julian Schulze
    Cornberg, Markus
    Zeuzem, Stefan
    Lampertico, Pietro
    JOURNAL OF HEPATOLOGY, 2022, 77 : S4 - S5
  • [34] EFFICACY AND SAFETY OF BULEVIRTIDE MONOTHERAPY GIVEN AT 2 MG OR 10 MG DOSE LEVEL ONCE DAILY FOR TREATMENT OF CHRONIC HEPATITIS DELTA: WEEK 48 PRIMARY ENDPOINT RESULTS FROM A PHASE 3 RANDOMIZED, MULTICENTER, PARALLEL-DESIGN STUDY
    Wedemeyer, Heiner
    Aleman, Soo
    Brunetto, Maurizia R.
    Blank, Antje
    Andreone, Pietro
    Bogomolov, Pavel
    Chulanov, Vladimir
    Mamonova, Nina
    Geyvandova, Natalia
    Morozov, Viacheslav
    Sagalova, Olga
    Stepanova, Tatyana V.
    Manuilov, Dmitry
    Shah, Vicki
    Suri, Vithika
    An, Qi
    Flaherty, John F.
    Osinusi, Anu
    zur Wiesch, Julian Schulze
    Cornberg, Markus
    Zeuzem, Stefan
    Lampertico, Pietro
    GASTROENTEROLOGY, 2023, 164 (06) : S1367 - S1368